| Bioactivity | Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. | ||||||||||||
| Invitro | The mechanism of action of Abeprazan is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1]. | ||||||||||||
| In Vivo | Abeprazan inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1]. | ||||||||||||
| Name | Abeprazan | ||||||||||||
| CAS | 1902954-60-2 | ||||||||||||
| Formula | C19H17F3N2O3S | ||||||||||||
| Molar Mass | 410.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. |
Abeprazan
CAS: 1902954-60-2 F: C19H17F3N2O3S W: 410.41
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H+, K+- ATPase by reversible potassium-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.